Official announcements from Yap Inc. — partnerships, awards, funding, and more.
Press Release
Yap signs a service agreement with Italy's Icarus — adapting an AI that takes the first call at medical institutions for Japan
Yap Inc. has signed a definitive service agreement, dated August 25, 2026, with Icarus S.r.l. (brand name: Icarus Technology), an Italian company providing a voice assistant in which AI answers calls to medical institutions. Following the memorandum of understanding signed on May 28, 2026, Yap now begins the research needed to adapt the service to Japanese healthcare settings. The name for the Japanese market is "Kyoko AI." No launch date in Japan has been decided at this time.
Yap Signs Memorandum of Understanding with Italy's Icarus S.r.l.
Yap Inc. has signed a Memorandum of Understanding (MoU) on a business partnership with Icarus S.r.l. (product brand: Icarus Technology), a company based in Sardinia, Italy. The MoU follows business development meetings in Tokyo, with the support of the Italian Trade Agency (ITA) and Regione Autonoma della Sardegna, and through SusHi Tech Tokyo, hosted by the Tokyo Metropolitan Government, and the venue of Tokyo Innovation Base. Icarus provides a multilingual AI voice assistant that automates patient phone reception for clinics; together the two companies aim to combine this with Yap's healthcare business and AI capabilities to expand in the Japanese market.
Yap Signs Partnership Agreement with Indonesian Digital Biobank Asa Ren
Yap Inc. has signed a business partnership agreement with Asa Ren, an Indonesian digital biobank company. Asa Ren operates Southeast Asia's first AI-powered digital biobank, integrating clinical and genomic data across diverse ethnic groups to advance personalized medicine and drug discovery. The two companies aim to expand awareness and adoption of Asa Ren's digital biobank.
Yap Signs Import Agreement with Bangladesh's UniMed UniHealth — First Bangladeshi Pharma to Enter Japan
Yap Inc. has signed an import agreement with UniMed UniHealth Pharmaceuticals Limited of Bangladesh. The agreement marks the first entry of a Bangladeshi pharmaceutical company into the Japanese market, beginning with Novotin, a biotin-based nutritional supplement.
Healthcare commentary shared by CEO Masaya Yamamoto on NewsPicks.
Platform
Filter by Tag
NewsPicksOctober 21, 2026
糖尿病「第4の細小血管症」― 肺機能低下を加える前に問うべきこと
At EASD 2026, a proposal emerged to classify pulmonary function decline as a 'fourth microvascular complication' of diabetes, alongside retinopathy, nephropathy, and neuropathy—conditions long managed under the principle of early, pre-symptomatic detection and intervention. If lung function deterioration also progresses silently, the same logic would seem to apply. That said, I am not convinced that spirometry should simply be added to the standard follow-up panel: the test is highly effort-dependent, maintaining reliable results across a busy diabetes clinic demands considerable staff time and training, and the evidence base for interventions that would actually improve prognosis after early detection remains thin. Before expanding screening, I would first want to assess how consistently the existing three-complication screens are being completed, and use that as a benchmark for gauging the priority of adding pulmonary assessment. Whether 'the fourth complication' takes hold as a clinical concept will ultimately depend on whether we can point to meaningful next steps once the finding is made.
Diabetic ComplicationsScreening PolicyPulmonary Function
The framework of 'preventive neurology' invites us to stop treating cognitive decline as an inevitable consequence of aging and to start managing it proactively. The 2024 Lancet Commission report's finding that 45% of dementia risk is modifiable is backed by multi-domain intervention studies such as FINGER and U.S. POINTER, while the observation that midlife hearing loss alone accounts for 7% of modifiable risk challenges existing health-screening systems that have long deprioritized sensory care. That said, implementation in Japan calls for sober assessment. Adhering to the MIND diet, individualizing exercise prescriptions, and reviewing medications using the ACB scale all demand time and expertise, yet there is no clear pathway to embed these into the current framework of specific health checkups and lifestyle guidance. For primary care physicians to take on ongoing cognitive prevention, both appropriate remuneration and sufficient consultation time are prerequisites. Dr. Spević's remark—'I can hand out a pamphlet, but what truly matters is habit formation'—captures the clinical reality precisely, yet the question of whether it is acceptable to leave that habit formation entirely to individual willpower remains open. We need to advance, in parallel, a conversation about how to close the gap between science that races ahead and policy that lags behind.
Large-scale data breaches in the medical and healthcare sector continue to mount, and the latest incident at an Asahi Kasei subsidiary—affecting up to 550,000 people—demands serious attention in the context of Japan's push for healthcare digitalization. What concerns me most is the nature of the data exposed: healthcare records are easily linked to highly sensitive personal information such as medical history, prescription records, and lifestyle data. Once that information leaks, it can lead to disadvantages in insurance enrollment or employment—a social impact of an entirely different dimension from financial data breaches. The core issue, I believe, is not simply the sophistication of technical defenses. What truly matters is whether security governance across the entire supply chain—including contractors and sub-contractors—is structurally sound. The more companies handle medical data, the more likely a 'weakest link' will emerge somewhere in that chain. We must keep asking how to design systems that preserve trust while capturing the benefits of digitalization; we cannot afford to accelerate data utilization while looking away from that question.
Healthcare Data SecuritySupply Chain RiskHealthcare Digitalization
Starting in June 2026, insurance coverage for medical nutritional supplements will be tightened in Japan, making it increasingly important for pharmacies to assess each patient's nutritional status. Malnutrition worsens prognosis and is easy to overlook, so someone must take responsibility for asking whether a given patient is truly getting enough—and pharmacies are a natural fit for that role. That said, if the policy stops at cutting benefits, the outcome risks becoming: those who can afford to pay out of pocket continue, while those who cannot simply stop. The people most vulnerable to malnutrition are often those living alone or experiencing cognitive decline—precisely the individuals least likely to seek help on their own, and most likely to be hurt by stricter coverage rules. Without a proactive outreach mechanism at the pharmacy level, the healthcare costs saved today will return as hospitalization and complications tomorrow. The real question is not whether to cover nutritional supplements universally or not at all, but whether Japan can shift to a system that measures who needs what and delivers it accordingly—one where pharmacies and clinicians share weight, dietary, and lab data to get the right nutrition to the right person. The true test of this tightening is whether it can serve as an entry point for individualizing nutritional care.
Nutritional CarePharmacy & Community HealthHealthcare Coverage Policy
New York State's measles emergency declaration—the first of its kind nationwide in 2025—is emblematic of a deeper issue. The MMR vaccine is roughly 97% effective with two doses, and herd immunity requires coverage of around 95%, yet vaccination rates have already fallen below that threshold in some areas. The root cause, in my view, is not the safety or efficacy of the vaccine itself, but a shift in the information environment: unfounded concerns spread through social media have coalesced into a sizable hesitant population. When trust in medicine erodes locally, diseases that were once eliminated come back—and this is not a problem unique to the United States. Japan, too, sees imported measles cases every year, and regional disparities in vaccination rates have been flagged as a concern. We need to keep grappling with how to sustain public trust before we find ourselves in a society that cannot act until a state of emergency has already been declared.
Infectious Disease ControlVaccine PolicyPublic Health
The framework of '14 modifiable risk factors' is significant in reframing dementia from an inevitable fate to something manageable, and the message that how we live in our 40s and 50s shapes our brain two to three decades later deserves far wider reach. At the same time, lecanemab and donanemab signal the dawn of disease-modifying treatment: CLARITY-AD showed roughly a 27% reduction in cognitive decline, while TRAILBLAZER-ALZ 2 found that 47% of the treatment group showed no decline over one year—though both drugs delay progression rather than stop it. This points to an emerging space between prevention and treatment: early detection and intervention, whose design remains unsettled. The real question for Japan is who takes responsibility for assessing risk from one's 40s onward. Blood pressure and weight are measured at routine check-ups, but no clear actor exists to connect those readings to brain health and track them continuously. Simply leaving risk-factor modification to individual willpower is not enough; the knowledge must be embedded in the architecture of health screenings and primary care before it can genuinely change how society as a whole grows old.
Dementia PreventionEarly Intervention & Disease-Modifying TherapyHealthcare System & Primary Care